This trial will test a new drug, EBT-101, on people with HIV who are taking antiretroviral therapy.
1 Primary · 0 Secondary · Reporting Duration: 48 weeks
Experimental Treatment
9 Total Participants · 3 Treatment Groups
Primary Treatment: EBT-101 · No Placebo Group · Phase 1
Age 18 - 65 · Male Participants · 10 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you: